Get the Stockscreener App
0.5026
4.71%
0.0226
After Hours:
.50
-0.0026
-0.52%
Fibrogen Inc stock is traded at $0.5026, with a volume of 468.68K.
It is up +4.71% in the last 24 hours and down -5.44% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
See More
Previous Close:
$0.48
Open:
$0.477
24h Volume:
468.68K
Relative Volume:
0.35
Market Cap:
$50.65M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-0.1715
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-0.71%
1M Performance:
-5.44%
6M Performance:
-51.20%
1Y Performance:
-70.78%
1-Day Range:
$0.4709
$0.51
1-Week Range:
$0.4635
$0.5414
52-Week Range:
$0.18
$2.93
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.5026 | 50.65M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
JPMorgan Chase & Co. Has $668,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Assenagon Asset Management S.A. Sells 415,812 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen (NASDAQ:FGEN) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
FibroGen Inc (NASDAQ: FGEN) Is Down -5.77% – Can It Revive? - Stocks Register
FibroGen, Inc. (NASDAQ:FGEN) Shares Purchased by Geode Capital Management LLC - Defense World
Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan
State Street Corp Lowers Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
FibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.com - MarketBeat
Court of Chancery Applies Well-Settled Principles To Dismiss Malone/Caremark ‘Hybrid’ Claims - JD Supra
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
Recent Investment Analysts’ Ratings Updates for FibroGen (FGEN) - Defense World
Fmr LLC Boosts Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
HC Wainwright Comments on FibroGen FY2024 Earnings - Defense World
HC Wainwright Upgrades FibroGen (NASDAQ:FGEN) to Strong-Buy - Defense World
HC Wainwright Estimates FibroGen FY2026 Earnings - Defense World
FibroGen started at buy by H.C. Wainwright (FGEN:NASDAQ) - Seeking Alpha
FibroGen shares rating initiated with Buy on product potential By Investing.com - Investing.com Canada
FibroGen appoints David DeLucia CFO - MSN
FibroGen shares rating initiated with Buy on product potential - Investing.com
FibroGen names David DeLucia as new CFO By Investing.com - Investing.com Canada
FibroGen Appoints David DeLucia as CFO - TipRanks
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - Marketscreener.com
FibroGen names David DeLucia as new CFO - Investing.com
FibroGen Appoints David DeLucia as Chief Financial Officer - GlobeNewswire
FibroGen Names David DeLucia as New CFO to Lead Financial Strategy and Drug Development Push - StockTitan
FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com - Defense World
Analyzing Unicycive Therapeutics (NASDAQ:UNCY) and FibroGen (NASDAQ:FGEN) - Defense World
FibroGen Inc earnings beat by $0.14, revenue topped estimates - Investing.com Nigeria
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN) - Defense World
ARMISTICE CAPITAL, LLC Reduces Stake in FibroGen Inc - GuruFocus.com
FibroGen Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com India
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: FibroGen reports strong Q3 sales, advances in oncology pipeline - Investing.com UK
FibroGen: Q3 Earnings Snapshot - mySA
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - MSN
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions By GuruFocus - Investing.com Canada
FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions - Yahoo Finance
FibroGen Reports Strong Q3 Growth and Future Plans - TipRanks
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):